RetinalGenix Technologies and LabCorp Partner on DNA/RNA/GPS Pharmaco-Genetic Mapping Platform

RetinalGenix Technologies has announced a partnership with LabCorp to advance the rollout of the RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping platform, a novel program aimed at integrating genetic testing with high-resolution retinal imaging to provide insights into both ocular and systemic diseases.

Enabling Comprehensive Genetic Testing and Retinal Imaging

Through this collaboration, patients can visit any LabCorp location in the United States to have blood, tears, nasal secretions, and saliva collected. These samples will be analyzed using proprietary algorithms developed by RetinalGenix and its DNA/RNA GPS analysis platform. The program allows patients to undergo genetic testing and retinal imaging anonymously, offering the possibility to correlate genetic and retinal biomarkers and work toward establishing a new standard for early detection of a wide range of health conditions.

Patients also have the option to have their data analyzed with specific algorithms developed by RetinalGenix, combined with DNA/RNA/GPS technology, to correlate findings with current and future biomarkers identified in both the eye and blood.

Supporting Early Detection and Protecting Patient Privacy

Larry Perich, DO, advisor for the DNA/RNA/GPS program, commented on the collaboration. “As the database of disease-associated biomarkers expands, we expect the value of these platforms for diagnosing both ocular and systemic diseases continues to grow, promising improved outcomes and more accessible care,” he said.

RetinalGenix emphasized that patients maintain full control of their health records, which remain anonymous and confidential throughout the process.

Future Directions: Retinal Imaging and Healthcare Access

The company also noted that high-resolution retinal imaging will soon be offered as a value-added service at various locations. These enhancements are intended to make screening more accessible, cost-effective, and capable of detecting disease earlier.

Jerry Katzman, MD, CEO of RetinalGenix Technologies, added that the company is actively working with regulators to establish CPT codes, which could help lower healthcare costs and improve access to essential evaluations.